Mithra Signs Binding Heads of Terms for Commercialization of Estelle® in South Korea with Women’s Health Specialist Hyundai pharm

  • Mithra eligible for milestone payments, recurring revenues and further sales-related royalty payments, with production of Estelle® for the South Korean market at the Mithra CDMO
  • With Estelle®, Hyundai Pharm aims to further expand its growing footprint in Women’s Health

Liège, Belgium, 5 June 2018 – Mithra (Euronext Brussels: MITRA), a company specialized in Women’s Health, today announced that it has signed a binding Heads of Terms agreement with Hyundai Pharm, a South Korean Women’s Health leader, for an exclusive license to commercialize Estelle® in South Korea. Estelle® is Mithra’s novel combined oral contraceptive (COC) product candidate currently in pivotal Phase III trials in Europe and Russia as well as in the US and Canada, with top line results expected in Q3 2018 and Q1 2019, respectively.